EP0402203A3 - Utilisation d'un dérivé de la statine dans le traitement des affections oculaires - Google Patents

Utilisation d'un dérivé de la statine dans le traitement des affections oculaires Download PDF

Info

Publication number
EP0402203A3
EP0402203A3 EP19900401452 EP90401452A EP0402203A3 EP 0402203 A3 EP0402203 A3 EP 0402203A3 EP 19900401452 EP19900401452 EP 19900401452 EP 90401452 A EP90401452 A EP 90401452A EP 0402203 A3 EP0402203 A3 EP 0402203A3
Authority
EP
European Patent Office
Prior art keywords
treatment
cyclohexyl
residue
ophthalmologic disorders
eye conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19900401452
Other languages
German (de)
English (en)
Other versions
EP0402203A2 (fr
Inventor
Dino Nisato
Gérard Le Fur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of EP0402203A2 publication Critical patent/EP0402203A2/fr
Publication of EP0402203A3 publication Critical patent/EP0402203A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention a pour objet l'utilisation du N-(pyridyl-3 propionyl)phénylalanyl-histidyl-(cyclohéxyl)statyl-N (dihydroxy-1,3 méthyl-2 propyl)isoleucinamide qui répond à la formule :
dans laquelle : Phe représente le résidu de la (L) phénylalanine ; His représente le résidu de la (L) histidine ; Ile représente le résidu de la (L) isoleucine et, (cyclohéxyl)Sta représente le résidu de la cyclohéxyle statine, c'est-à-dire de l'acide (3S, 4S) amino-4 cyclohéxyl-5 hydroxy-3 pentanoïque, pour la préparation de médicaments utiles dans le traitement des affections oculaires.
Application : traitement des affections oculaires.
EP19900401452 1989-06-05 1990-05-31 Utilisation d'un dérivé de la statine dans le traitement des affections oculaires Ceased EP0402203A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8907410A FR2647675B1 (fr) 1989-06-05 1989-06-05 Utilisation d'un derive de la statine dans le traitement des affections oculaires
FR8907410 1989-06-05

Publications (2)

Publication Number Publication Date
EP0402203A2 EP0402203A2 (fr) 1990-12-12
EP0402203A3 true EP0402203A3 (fr) 1992-07-22

Family

ID=9382375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900401452 Ceased EP0402203A3 (fr) 1989-06-05 1990-05-31 Utilisation d'un dérivé de la statine dans le traitement des affections oculaires

Country Status (5)

Country Link
US (1) US5134124A (fr)
EP (1) EP0402203A3 (fr)
JP (1) JPH0334934A (fr)
CA (1) CA2018209A1 (fr)
FR (1) FR2647675B1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7581000A (en) 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
US8889112B2 (en) * 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US20020082288A1 (en) * 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
GB0011769D0 (en) * 2000-05-17 2000-07-05 Ball Burnishing Mach Tools A surface conditioning tool employing compressed non-woven fibres
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
AU2002221091A1 (en) 2000-12-11 2002-06-24 Toyo Boseki Kabushiki Kaisha High strength polyethylene fiber
JP2007512347A (ja) * 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
WO2005105069A1 (fr) * 2004-04-26 2005-11-10 Alcon, Inc. Statines pour le traitement de l'hypertension oculaire et du glaucome
JP3756921B1 (ja) 2004-10-18 2006-03-22 日産ディーゼル工業株式会社 還元剤容器の構造
JP4064396B2 (ja) 2004-10-28 2008-03-19 日産ディーゼル工業株式会社 還元剤容器の構造
KR20080018268A (ko) 2005-06-17 2008-02-27 리지너크스 바이오 파마소티컬스, 인코포레이티드 조직 악화, 부상 또는 손상을 치료하거나 또는 예방하기위한 엘케이케이티이티 및/또는 엘케이케이티엔티 조성물들및 그 방법
MY147573A (en) 2005-06-23 2012-12-31 Teijin Aramid Gmbh Bullet proof laminate and trauma pack
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
DK2950648T3 (da) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf
CA2899342C (fr) 2013-02-01 2021-09-21 Ocularis Pharma, Llc Procedes et compositions pour l'administration ophtalmique quotidienne de phentolamine pour ameliorer les performances visuelles
US9499621B2 (en) 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
CA3168400A1 (fr) 2020-02-19 2021-08-26 Vestlandets Innovasjonsselskap As Traitement de la vascularisation corneenne
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2026064542A1 (fr) 2024-09-18 2026-03-26 Cognition Therapeutics, Inc. Sels de fumarate de 2-(tert-butoxy)-4-(3-méthyl-3-(5- (méthylsulfonyl)isoindolin-2-yl)butyl)phénol sous des formes solides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0211744A1 (fr) * 1985-07-31 1987-02-25 Sanofi Dérivés aminoalcools peptidiques contenant un atome de carbone tetrasubstitué inhibiteurs de la rénine et des protéases acides - Procédé d'obtention et compositions pharmaceutiques
EP0311012A2 (fr) * 1987-10-06 1989-04-12 Abbott Laboratories Traitement du glaucome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906613A (en) * 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0211744A1 (fr) * 1985-07-31 1987-02-25 Sanofi Dérivés aminoalcools peptidiques contenant un atome de carbone tetrasubstitué inhibiteurs de la rénine et des protéases acides - Procédé d'obtention et compositions pharmaceutiques
EP0311012A2 (fr) * 1987-10-06 1989-04-12 Abbott Laboratories Traitement du glaucome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF HYPERTENSION, vol. 7, suppl. 2, 1989, pages S33-S35, Current Sciences Ltd; C. LACOUR et al.: "Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca" *

Also Published As

Publication number Publication date
JPH0334934A (ja) 1991-02-14
FR2647675A1 (fr) 1990-12-07
US5134124A (en) 1992-07-28
FR2647675B1 (fr) 1994-05-20
CA2018209A1 (fr) 1990-12-04
EP0402203A2 (fr) 1990-12-12

Similar Documents

Publication Publication Date Title
CA2170047A1 (fr) Derive de l'androstenone
CA2227977A1 (fr) Utilisation dans une composition d'un extrait d'au moins une labiee
CA2245125A1 (fr) Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
CA2173543A1 (fr) Composes de type ceramides, leur procede de preparation et leur utilisation
RU93047799A (ru) Композиции, содержащие ретиноевые кислоты и токоферол
TNSN94035A1 (fr) Composition veterinaire
KR890701559A (ko) 3-인돌피루브산 유도체 및 그의 제약 용도
BR9505938A (pt) Composto processo para sua preparação processos para tratamento e prevenção de doenças processo de elevação dos níveis de HDL plasmático e composiç o farmacêutica
LV12766A (lv) Composition of l-dopa esters
NO944752D0 (no) Rensede DNase-former
BR9306399A (pt) Composição farmacéutica para uso no tratamento de glaucoma
CA2285037A1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
EP1541128A3 (fr) Composition cosmétique contenant des dérivés de l'acide cinnamique et leur utilisation
ATE45941T1 (de) Medizinische zusammensetzung zur behandlung von allergie-krankheiten.
FR2647675B1 (fr) Utilisation d'un derive de la statine dans le traitement des affections oculaires
CA2147807A1 (fr) Composes bicycliques-aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
PT98692A (pt) Processo para a preparacao de composicoes farmaceuticas contendo emulsoes de calcitonina para administracao por via nasal
DE69333723D1 (de) Pharmazeutische zubereitung auf der basis von rhamnolipid gegen dermatologische erkrankungen
EP0138720A3 (fr) Nouveaux benzenesulfonamides n-cyclises, leur procédé de préparation et leur utilisation comme substance active de compositions pharmaceutiques
MA21902A1 (fr) Procede pour la preparation de peptitides hemoregulateurs et des compositions pharmaceutiques les comtenant .
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
CA2170065A1 (fr) Composes bi-aromatiques derives d'amide, compositions pharmaceutiques et cosmetiques les contenant et utilisations
KR960003729A (ko) 항과혈당증 작용을 지닌 약제
FR2388828A1 (fr) 5-iodo-5'-amino-2',5'-didesoxycytidine et medicament contenant cette substance ou un sel de celle-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19901224

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELF SANOFI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940609

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19950918